MARKET

GNMSF

GNMSF

Genmab A/S
OTCPK
270.60
NaN%
Closed 09:30 06/03 EDT
OPEN
--
PREV CLOSE
270.60
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
352.00
52 WEEK LOW
196.20
MARKET CAP
16.61B
P/E (TTM)
20.50
1D
5D
1M
3M
1Y
5Y
1D
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
Barchart · 5d ago
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Barchart · 05/12 12:46
Major Shareholder Announcement
Barchart · 05/08 14:05
Genmab A/S Share Capital Reduction
Barchart · 04/17 09:56
Major Shareholder Announcement
Barchart · 04/14 09:44
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026
Barchart · 04/14 05:23
Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
Barchart · 04/13 08:35
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
Barchart · 04/01 14:19
More
About GNMSF
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Webull offers Genmab A/S stock information, including OTCPK: GNMSF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GNMSF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GNMSF stock methods without spending real money on the virtual paper trading platform.